{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:01:49Z","timestamp":1792425709052,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UCB Pharma AS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Several innovative treatments are expected for myasthenia gravis (MG) in the coming years. Healthcare payers usually require cost-effectiveness analyses before reimbursement. We aimed to investigate resource utilization and direct medical costs for patients with MG treated with intravenous immunoglobulin (IVIg) to inform such analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We identified patients with MG in the Norwegian Patient Registry based on at least two hospital encounters with an MG diagnosis (ICD-10 G70.0) from 1 Jan 2010 to 31 Dec 2021. IVIg treatment was identified by medical procedure and Anatomical Therapeutic Chemical (ATC) codes (RPGM05 and J06BA02). Using Diagnosis-Related Group (DRG) cost weights, we estimated direct medical costs for each year following the first MG diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Over the study period, 1083 patients were diagnosed with MG in Norway, of whom 155 (14.3%) were treated with IVIg. No significant differences in age or sex were observed between IVIg and non-IVIg patients. Compared with non-IVIg patients, IVIg-patients had 2.3 times higher direct medical costs during the first year after MG diagnosis (EUR 35,714 vs. EUR 15,457) and 3.1 times higher costs during the second year (EUR 19,119 vs. EUR 6256). In the fifth year after diagnosis, IVIg-patients still had higher costs and resource utilization than non-IVIg patients (EUR 9953 vs. EUR 5634).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>IVIg treatment represents an important marker for high direct medical costs among patients with MG. The costs continue to be high during the first five years after MG diagnosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-024-12768-5","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T12:10:29Z","timestamp":1734005429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) \u2013 a register-based study"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0766-2870","authenticated-orcid":false,"given":"Christoffer","family":"Bugge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-6731","authenticated-orcid":false,"given":"Ingrid","family":"Engebretsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-6010","authenticated-orcid":false,"given":"Ivar S\u00f8nb\u00f8","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Magnus","family":"S\u00e6ther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-6065","authenticated-orcid":false,"given":"Ingrid","family":"Lindberg-Schager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Arneberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Erik","family":"Gilhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"issue":"26","key":"12768_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. NEJM 375(26):2570\u20132581","journal-title":"NEJM"},{"issue":"2","key":"12768_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/sjmms.sjmms_80_22","volume":"10","author":"D Aljaafari","year":"2022","unstructured":"Aljaafari D, Ishaque N (2022) Thymectomy in myasthenia gravis: a narrative review. Saudi J Med Med Sci 10(2):97\u2013104","journal-title":"Saudi J Med Med Sci"},{"issue":"7","key":"12768_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochm\u00fcller H (2020) Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics 38(7):715\u2013728","journal-title":"Pharmacoeconomics"},{"key":"12768_CR4","unstructured":"Arumugham VB, Rayi A. Intravenous Immunoglobulin (IVIG) Treasure Island (FL): StatPearls; 2023 [updated 2023 July 3rd. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554446\/."},{"key":"12768_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16233","author":"I Engebretsen","year":"2024","unstructured":"Engebretsen I, Gilhus NE, Kristiansen IS, Saether EM, Lindberg-Schager I, Arneberg F et al (2024) The epidemiology and societal costs of myasthenia gravis in\u00a0Norway: a non-interventional study using national registry\u00a0data. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.16233","journal-title":"Eur J Neurol."},{"issue":"6","key":"12768_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Marano A, Krueger A, Sanders DB (2011) Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle Nerve 44(6):907\u201311","journal-title":"Muscle Nerve"},{"key":"12768_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jocn.2016.11.003","volume":"38","author":"KK Sonkar","year":"2017","unstructured":"Sonkar KK, Bhoi SK, Dubey D, Kalita J, Misra UK (2017) Direct and indirect cost of myasthenia gravis: a prospective study from a tertiary care teaching hospital in India. J Clin Neurosci 38:114\u2013117","journal-title":"J Clin Neurosci"},{"issue":"3","key":"12768_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.22327","volume":"45","author":"JT Guptill","year":"2012","unstructured":"Guptill JT, Sharma BK, Marano A, Soucy A, Krueger A, Sanders DB (2012) Estimated cost of treating myasthenia gravis in an insured U.S. population. Muscle Nerve 45(3):363\u20136","journal-title":"Muscle Nerve"},{"key":"12768_CR9","unstructured":"Statistics Norway(2023) Table 07459: Population, by sex and one-year age groups (M) 1986\u20132023"},{"issue":"10","key":"12768_CR10","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1007\/s00415-021-10544-3","volume":"268","author":"A Wilf-Yarkoni","year":"2021","unstructured":"Wilf-Yarkoni A, Lotan I, Steiner I, Hellmann MA (2021) Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis. J Neurol 268(10):3871\u20133877","journal-title":"J Neurol"},{"key":"12768_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120480","volume":"443","author":"CZ Qi","year":"2022","unstructured":"Qi CZ, Hughes T, Gelinas D, Li Y, Goyal A, Brauer E et al (2022) Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States. J Neurol Sci 443:120480","journal-title":"J Neurol Sci"},{"issue":"6","key":"12768_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/mus.24259","volume":"50","author":"C Eienbr\u00f6ker","year":"2014","unstructured":"Eienbr\u00f6ker C, Seitz F, Spengler A, Kurz H, Seipelt M, Sommer N et al (2014) Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation. Muscle Nerve 50(6):999\u20131004","journal-title":"Muscle Nerve"},{"issue":"2","key":"12768_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/ene.14547","volume":"28","author":"M Alcantara","year":"2021","unstructured":"Alcantara M, Sarpong E, Barnett C, Katzberg H, Bril V (2021) Chronic immunoglobulin maintenance therapy in myasthenia gravis. Eur J Neurol 28(2):639\u2013646","journal-title":"Eur J Neurol"},{"issue":"8","key":"12768_CR14","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.healthpol.2021.05.008","volume":"125","author":"C Bugge","year":"2021","unstructured":"Bugge C, S\u00e6ther EM, Brustugun OT, Kristiansen IS (2021) Societal cost of cancer in Norway -results of taking a broader cost perspective. Health Policy 125(8):1100\u20131107","journal-title":"Health Policy"},{"key":"12768_CR15","first-page":"1336","volume":"132","author":"I Bakken","year":"2012","unstructured":"Bakken I, Gystad S, Christensen \u00d8, Huse U, Lar\u00f8nningen S, Nyg\u00e5rd J et al (2012) Comparison of data from the Norwegian patient register and the cancer registry of Norway. J Norwegian Med Assoc 132:1336\u20131340","journal-title":"J Norwegian Med Assoc"},{"issue":"2","key":"12768_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","volume":"13","author":"C Heatwole","year":"2011","unstructured":"Heatwole C, Johnson N, Holloway R, Noyes K (2011) Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis 13(2):85\u201394","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"12768_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/mus.24960","volume":"53","author":"JC Furlan","year":"2016","unstructured":"Furlan JC, Barth D, Barnett C, Bril V (2016) Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle Nerve 53(6):872\u2013876","journal-title":"Muscle Nerve"},{"issue":"6","key":"12768_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A (2010) Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 68(6):797\u2013805","journal-title":"Ann Neurol"},{"key":"12768_CR19","doi-asserted-by":"publisher","first-page":"175628642211503","DOI":"10.1177\/17562864221150327","volume":"16","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A (2023) Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther Adv Neurol Disord 16:17562864221150328","journal-title":"Ther Adv Neurol Disord"},{"key":"12768_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-333097","author":"J Vissing","year":"2024","unstructured":"Vissing J, Atula S, Savolainen M, Meht\u00e4l\u00e4 J, Mehkri L, Olesen TB et al (2024) Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2023-333097","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12768_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palaces J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nature Rev Disease Primers. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nature Rev Disease Primers"},{"issue":"5","key":"12768_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","volume":"31","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S, Leopoldsdottir MO et al (2024) Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol 31(5):e16229","journal-title":"Eur J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12768-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:41:35Z","timestamp":1738172495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12768-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["12768"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12768-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christoffer Bugge, Ingrid Engebretsen, Ivar S\u00f8nb\u00f8 Kristiansen, and Erik Magnus S\u00e6ther are affiliated with Oslo Economics and have all completed consultancy assignments for several pharmaceutical companies in recent years. Ingrid Lindberg-Schager and Fredrik Arneberg work at UCB Pharma. Nils Erik Gilhus has received financial support from UCB, Argenx, Janssen, Merck, Roche, Alexion and Immunovant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"15"}}